Found 11 matching trials
Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer
PHASE2RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor grow...
Location
Kantonspital Aarau
Is Hip Range of Motion Relevant in the Treatment of Chronic Low Back Pain?
NAThe study will be carried out at the Faculty of Nursing and Physiotherapy o...
Effects of Ballistic Six Exercises With and Without Blood Flow Restriction in Cricket Players
NACricket is not only a widely played team sport, but it also involves intric...
Clinical Trial of the Effect of Different Categories of Adhesive System
PHASE2This study aims to evaluate the clinical effectiveness of contemporary resi...
Location
Universidad Valparaiso
Controlled Study Comparing REPaiR® and MIST Therapies for Treatment of Periodontitis
NAA comparison of laser (REPaiR) compared with minimally invasive surgical th...
Effect of Pilates Core Stabilization in Adjunct With Plyometric Shoulder Training on Low Back Pain in Fast Bowlers(RCT)
NAThis RCT will seek to determine both the Pilates core stabilization and ply...
Status
Active Not Recruiting
Location
Pakistan Cricket Board
Effect of 8-week Incremental Elastic-Resistance Kick Training in Taekwondo Athlete's
NAThis study aimed to assess the effects of an 8-week incremental elastic-res...
Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.
PHASE3Rationale:
In patients with metastatic breast cancer, fragments of tumor D...
Location
Multiple Locations
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
PHASE1Open-label, multi-dose, single-arm, multi-center, Phase 1/2 study conducted...
Location
City of Hope National Medical Center
Treatments Being Tested
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days offFlotetuzumab 10 ng/kg/day, 4 days on and 3 days offFlotetuzumab 30 ng/kg/day, 4 days on and 3 days offFlotetuzumab 100 ng/kg/day, 4 days on and 3 days offFlotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in doseFlotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in doseFlotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in doseFlotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in doseFlotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in doseRuxolitinibFlotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
PHASE1The primary objectives are:
Phase 1b:
* To determine the maximum tolerate...
Location
USC/Norris Comprehensive Cancer Center